Oncopeptides, a pharmaceutical company, has shared new findings from a clinical trial that show the drug Pepaxti can be safely and effectively used in people with multiple myeloma who also have moderate to severe kidney problems. This group makes up about half of all multiple myeloma patients and often has worse long-term health outcomes. The study, called the BRIDGE study, was published in a medical journal and looked at how Pepaxti, combined with another medication called dexamethasone, works in patients with reduced kidney function. The researchers found that adjusting the dose of Pepaxti based on kidney function helps control the disease without causing harm or making kidney problems worse. Dr. Ludek Pour, who led the study, explained that these findings are very important because they show that by carefully adjusting the dose, doctors can keep the disease under control and maintain patient safety, even in this vulnerable group. The study found that patients with moderate kidney problems who started treatment with a lower dose of 30 mg had a consistent safety profile and treatment responses that matched earlier studies in broader groups of patients. Additionally, the kidney function of these patients either stayed the same or even improved slightly during treatment, suggesting that Pepaxti does not hurt the kidneys at the doses studied. The key results showed that 47.6% of patients receiving a 40 mg starting dose responded to treatment, while 70% of those receiving 30 mg responded. The median time until the disease got worse was 8.6 months for the 40 mg group and 7.7 months for the 30 mg group. No new safety concerns were found, and the most common side effects were related to the blood, which is consistent with what was seen in earlier studies. Stefan Norin, the Chief Medical Officer at Oncopeptides, said that this study adds important scientific evidence to how Pepaxti should be used, especially for patients with kidney problems. He also mentioned that by showing Pepaxti can be safely used at an optimized 30 mg dose, the BRIDGE study gives doctors the confidence to use this treatment in a wider range of patients.